Suarez Anna, Lahti Jari, Lahti-Pulkkinen Marius, Girchenko Polina, Czamara Darina, Arloth Janine, Malmberg Anni Lk, Hämäläinen Esa, Kajantie Eero, Laivuori Hannele, Villa Pia M, Reynolds Rebecca M, Provençal Nadine, Binder Elisabeth B, Räikkönen Katri
Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland.
Turku Institute for Advanced Studies, University of Turku, Turku, Finland.
Neurobiol Stress. 2020 Nov 21;13:100275. doi: 10.1016/j.ynstr.2020.100275. eCollection 2020 Nov.
Maternal depression and anxiety during pregnancy may enhance fetal exposure to glucocorticoids (GCs) and harm neurodevelopment. We tested whether a novel cross-tissue polyepigenetic biomarker indicative of exposure to GC is associated with mental and behavioral disorders and their severity in children, possibly mediating the associations between maternal prenatal depressive and anxiety symptoms and these child outcomes.
Children (n = 814) from the Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction (PREDO) study were followed-up from birth to age 7.1-10.7 years. A weighted polyepigenetic GC exposure score was calculated based on the methylation profile of 24 CpGs from umbilical cord blood. Child diagnosis of mental and behavioral disorder (n = 99) and its severity, defined as the number of days the child had received treatment (all 99 had received outpatient treatment and 8 had been additionally in inpatient treatment) for mental or behavioral disorder as the primary diagnosis, came from the Care Register for Health Care. Mothers (n = 408) reported on child total behavior problems at child's age of 2.3-5.8 years and their own depressive and anxiety symptoms during pregnancy (n = 583).
The fetal polyepigenetic GC exposure score at birth was not associated with child hazard of mental and behavioral disorder (HR = 0.82, 95% CI 0.54; 1.24, p = 0.35) or total behavior problems (unstandardized beta = -0.10, 95% CI -0.31; 0.10, p = 0.33). However, for one standard deviation decrease in the polyepigenetic score, the child had spent 2.94 (95%CI 1.59; 5.45, p < 0.001) more days in inpatient or outpatient treatment with any mental and behavioral disorder as the primary diagnosis. Criteria for mediation tests were not met.
These findings suggest that fetal polyepigenetic GC exposure score at birth was not associated with any mental or behavioral disorder diagnosis or mother-rated total behavior problems, but it may contribute to identifying children at birth who are at risk for more severe mental or behavioral disorders.
孕期母亲的抑郁和焦虑可能会增加胎儿暴露于糖皮质激素(GCs)的水平,并损害神经发育。我们测试了一种新型的跨组织多表观遗传生物标志物(指示GC暴露情况)是否与儿童的精神和行为障碍及其严重程度相关,该生物标志物可能介导了母亲产前抑郁和焦虑症状与这些儿童结局之间的关联。
来自先兆子痫和宫内生长受限预测与预防(PREDO)研究的814名儿童从出生随访至7.1 - 10.7岁。基于脐带血中24个CpG的甲基化谱计算加权多表观遗传GC暴露评分。儿童精神和行为障碍的诊断(n = 99)及其严重程度(定义为儿童因精神或行为障碍作为主要诊断接受治疗的天数,所有99名儿童均接受了门诊治疗,8名儿童还接受了住院治疗)来自医疗保健护理登记册。母亲(n = 408)报告了孩子在2.3 - 5.8岁时的总体行为问题以及她们自己孕期的抑郁和焦虑症状(n = 583)。
出生时的胎儿多表观遗传GC暴露评分与儿童患精神和行为障碍的风险(HR = 0.82,95%CI 0.54;1.24,p = 0.35)或总体行为问题(未标准化β = -0.10,95%CI -0.31;0.10,p = 0.33)均无关联。然而,多表观遗传评分每降低一个标准差,儿童因任何精神和行为障碍作为主要诊断而接受住院或门诊治疗的天数就会增加2.94天(95%CI 1.59;5.45,p < 0.001)。未满足中介检验的标准。
这些发现表明,出生时的胎儿多表观遗传GC暴露评分与任何精神或行为障碍诊断或母亲评定的总体行为问题均无关联,但它可能有助于识别出生时患更严重精神或行为障碍风险较高的儿童。